SecBot SecBot

NSPR drug pipeline

InspireMD, Inc. · 2 rated drugs
$0.6500
+8.3% 1-day · Nov 17
Next catalyst
Dec 2026
CGuard Prime NDA filing
Typical move on FDA news
±0.9%
1-day, median of 3 events
IV rank
No data
No current options data
Rated drugs
2
1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. Dec 2026
    CGuard Prime
    NDA filing · Carotid Artery Stenting (CAS) procedures

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseApproved (FDA PMA)
Time to marketCGuard Prime is already FDA-approved and was commercially launched for CAS procedures before the May 2026 recall paused U.S. sales. The new TCAR indication was approved November 12, 2026, and the company plans a U.S. commercial relaunch in Q4 2026 pending FDA approval of the 80cm delivery system.

CGuard Prime Updated Nov 13

Dec 2026
Next catalyst
NDA filing · Dec 2026 · Carotid Artery Stenting (CAS) procedures
What to watch

The next catalyst is FDA approval of the CGuard Prime 80cm delivery system, anticipated in Q4 2026 (any day now). Approval would enable a fuller U.S. commercial relaunch after the 135cm recall. Separately, the company plans to submit a PMA supplement for an enhanced CGuard Prime for CAS procedures in December 2026. The stock's ~17% drop today reflects the dilutive $37.5M offering, not the TCAR approval itself.

Bull case
  • FDA approved CGuard Prime for TCAR procedures on Nov 12, 2026, doubling the U.S. addressable market to ~75,000 annual carotid stenting procedures (adding 35,000+ TCAR procedures).
  • The CGUARDIANS II pivotal trial supporting the TCAR approval reported 100% acute device success and zero adverse events at 30 days, a strong safety/efficacy profile.
  • Analyst consensus is bullish: 8 Buy/Strong Buy vs 1 Hold (0 Sell) as of Nov 2026, with a mean price target of $3.33 (versus the current ~$0.64 stock price).
Bear case
  • Voluntary recall of the CGuard Prime 135cm delivery system in May 2026 paused U.S. commercialization and forced a 2026 revenue guidance withdrawal, raising questions about manufacturing/quality execution.
  • The $37.5M public offering priced on Nov 13, 2026 is heavily dilutive: 7.34M shares plus pre-funded warrants for 50.35M shares and common warrants for 43.27M shares, pressuring the stock (down ~17% today to $0.64).
  • Cash burned quickly: $19.2M at Q3 2026 vs $54.2M at year-end 2025, and the company has a history of losses and a going-concern risk.
● neutral
Impact
PhasePivotal Study (CGUARDIANS III IDE)
Time to marketThe CGUARDIANS III pivotal study began enrolling in June 2026 with no disclosed completion date. The company targets a U.S. commercial launch in 2027 if the study succeeds and FDA approval follows, but this timeline is aspirational and subject to clinical results and regulatory review.

SwitchGuard Updated Nov 13

What to watch

SwitchGuard is an early-stage pipeline asset with no hard dated catalyst in the next 12 months. The CGUARDIANS III pivotal study began enrolling in June 2026; watch for enrollment completion updates or interim data announcements, but no timeline has been disclosed. The stock's near-term moves will be driven by the just-approved CGuard Prime TCAR commercial launch and the company's ability to execute after the recent delivery-system recall and dilutive $37.5M offering.

Bull case
  • SwitchGuard addresses a clear unmet need: a neuroprotection shunt for TCAR procedures that works with InspireMD's own CGuard Prime stent platform, potentially offering a combined solution versus competitors' separate components.
  • The FDA approved the IDE for the CGUARDIANS III pivotal study in May 2026, and the first patient was enrolled in June 2026, showing regulatory and clinical momentum.
  • InspireMD just received FDA approval for CGuard Prime in TCAR (Nov 12, 2026), which approximately doubles the U.S. addressable market for its stent platform and creates a natural cross-sell opportunity for SwitchGuard if approved.
Bear case
  • SwitchGuard is still in an early-stage pivotal study (CGUARDIANS III) with no completion or readout date disclosed; a U.S. commercial launch is targeted for 2027 at the earliest, years away.
  • Silk Road Medical's ENROUTE Transcarotid Neuroprotection System PLUS is already on the market and established in TCAR procedures, giving it a first-mover advantage.
  • InspireMD's recent voluntary recall of its CGuard Prime 135cm delivery system (May 2026) and withdrawal of 2026 revenue guidance raised execution concerns, and the company just priced a dilutive $37.5M public offering (Nov 13, 2026).

Other drugs in filings and trials

no drug report yet
  • CGuard Prime 80 cm Last: Approval · Sep 21, 2026

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
Sep 21, 2026CGuard Prime 80 cmApproval−1.3%−10.4%
Jun 30, 2026CGuard PrimeBLA filed0.0%+1.5%
May 1, 2026CGuard Prime 80 cmApproval−0.8%−2.5%